Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:06:15.714Z.
Calculation as of: 2026-10-06T15:06:15.714Z.
Quote observation: 2026-10-06T15:04:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 781bf18d5b555faf6525e3bbfdfcc877af608ad86c98afd042bd19dc8220ce7c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Cardiol Therapeutics Inc.
Market Cap
$153.31M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$154.07M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$151.52M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$155.61M
Price/OCF Ratio
N/A
TTM Avg
78.89
3Y Avg
78.89
5Y Avg
78.89
Market Cap
$155.86M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$150.59M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiol Therapeutics Inc. (CRDL) | $153.31M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $154.07M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $152.34M | N/A | 32.64 | 32.64 | 32.64 |
| LifeMD, Inc. (LFMDP)vs › | $154.72M | N/A | 109.43 | 140.00 | 140.00 |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.52M | N/A | N/A | N/A | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $155.61M | N/A | 78.89 | 78.89 | 78.89 |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $150.59M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.63M | N/A | 113.17 | 139.63 | 64.33 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
